Artículo
Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis
Autor/es | Vázquez-Bourgon, Javier
Ortiz García de la Foz, Víctor Gómez-Revuelta, Marcos Mayoral-van Son, Jaqueline Juncal-Ruiz, María Garrido-Torres, Nathalia Crespo Facorro, Benedicto |
Departamento | Universidad de Sevilla. Departamento de Psiquiatría |
Fecha de publicación | 2022-05-31 |
Fecha de depósito | 2023-06-12 |
Publicado en |
|
Resumen | Objective
Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. ... Objective Aripiprazole and risperidone are 2 of the most used second-generation antipsychotics (SGAs) worldwide. Previous evidence shows a similar effect of these SGAs on weight and metabolic changes in the short term. However, a longer period is necessary for a better assessment of the SGA´s metabolic profile. We aimed to compare the long-term (1-year) metabolic profile of these 2 antipsychotics on a sample of drug-naïve first episode-psychosis (FEP) patients. Methods A total 188 drug-naïve patients, suffering from a first episode of non-affective psychosis (FEP), were randomly assigned to treatment with either aripiprazole or risperidone. Weight and glycemic/lipid parameters were recorded at baseline and after 1-year follow-up. Results We observed significant weight increments in both groups (9.2 kg for aripiprazole and 10.5 kg for risperidone) after 1 year of treatment. Despite this, weight and body mass index changes did not significantly differ between treatment groups (P > .05). Similarly, both treatment groups presented similar metabolic clinical impact with a comparable increase in the proportion of participants meeting criteria for metabolic disorders such as obesity or hypercholesterolemia, but not for metabolic syndrome (Δ9.2% vs Δ4.3%) or hypertriglyceridemia (Δ21.9% vs Δ8.0%), where aripiprazole showed worse outcomes than risperidone. Conclusion This study shows that aripiprazole and risperidone share a similar long-term metabolic profile. After 1 year of antipsychotic treatment, drug-naïve FEP patients in both treatment groups presented a significant increase in weight and metabolic changes, leading to a greater prevalence of metabolic disorders. |
Agencias financiadoras | AstraZeneca Bristol-Myers Squibb Instituto de Investigacion Sanitaria Valdecilla Instituto de Salud Carlos III Janssen Johnson Johnson Lundbeck Pfizer |
Identificador del proyecto | INT/A20/04
INT/A21/10 PI020499 PI050427 PI060507 |
Cita | Vázquez-Bourgon, J., Ortiz García de la Foz, V., Gómez-Revuelta, M., Mayoral-van Son, J., Juncal-Ruiz, M., Garrido-Torres, N. y Crespo Facorro, B. (2022). Aripiprazole and Risperidone Present Comparable Long-Term Metabolic Profiles: Data From a Pragmatic Randomized Controlled Trial in Drug-Naïve First-Episode Psychosis. International Journal of Neuropsychopharmacology (IJNP), 25 (10), 795-806. https://doi.org/10.1093/ijnp/pyac033. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Aripiprazole and Risperidone ... | 1.470Mb | [PDF] | Ver/ | |